查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602172

治疗性血浆交换市场：按技术、适应症、产品和最终用户划分 - 全球预测 2025-2030 年

Therapeutic Plasma Exchange Market by Technology (Centrifugation, Membrane Separation), Indication (Hematologic Disorders, Metabolic Disorders, Neurological Disorders), Product, End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年治疗性血浆交换市场价值为7.9204亿美元，预计到2024年将达到8.7853亿美元，复合年增长率为9.81%，预计到2030年将达到15.2584亿美元。

治疗性血浆置换 (TPE) 是一种重要的医疗程序，涉及血浆的取出、治疗和回输，以治疗各种健康状况，包括自体免疫疾病、神经系统疾病和血液疾病。 TPE 的需求在于其清除血液中致病物质的能力，这对于对常规治疗没有反应的患者至关重要。 TPE已应用于治疗Guillain-Barré二氏症候群、重症肌无力、血栓性血小板低下紫斑症、非典型溶血性尿毒症症候群等疾病，医院和专科诊所是主要终端用户。由于自体免疫疾病的流行、医疗基础设施的进步以及人口老化的加剧，TPE 市场正在不断增长。技术进步，例如开发更有效率、更安全的单采设备，以及对 TPE 治疗益处的认识不断提高，是关键的成长动力。然而，市场面临手术成本高、报销政策有限以及对熟练医疗专业人员的需求等挑战。此外，发展中地区熟练技术人员的稀缺和取得机会有限也阻碍了成长。儘管存在这些挑战，但仍存在将应用扩展到新的自体免疫疾病以及在具有成本效益且易于使用的单采设备方面进行创新的机会。对研发以及策略联盟和伙伴关係的投资有可能加速成长并扩大应用范围。公司可以利用资料分析来优化程序并改善患者的治疗效果。此外，远端医疗可以支援远端监控和治疗后护理，付加服务提供的价值。然而，有关医疗设备认证的法规和血浆采购的道德影响凸显了需要仔细关注的领域。为了保持竞争力，公司应专注于个人化医疗方法并整合先进技术，提供适合患者独特需求的治疗性血浆置换解决方案。

主要市场统计
基准年[2023] 79204万美元
预测年份 [2024] 87853万美元
预测年份 [2030] 15.2584亿美元
复合年增长率（%） 9.81%

市场动态：快速发展的治疗性血浆交易市场的关键市场洞察

供需的动态交互作用正在改变治疗性血浆置换市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 由于自体免疫疾病和心臟病的盛行率不断增加，需要进行治疗性血浆置换
    • 单采技术的进步
  • 市场限制因素
    • 与设备和治疗性血浆置换程序相关的成本
  • 市场机会
    • 神经肌肉疾病治疗性血浆置换技术与免疫调节作用的进展
    • 儿科加护治疗中治疗性血浆置换 (TPE) 的需求迅速增长
  • 市场挑战
    • TPE 中与血浆分离术相关的併发症

波特五力：驾驭治疗性血浆交换市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解治疗性血浆交换市场的外部影响

外部宏观环境因素在塑造治疗性血浆交换市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解治疗性血浆置换市场的竞争格局

治疗性血浆交换市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵治疗性血浆置换市场供应商的绩效评估

FPNV 定位矩阵是评估治疗性血浆置换市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 由于自体免疫疾病和心臟病盛行率上升，需要进行治疗性血浆置换
      • 单采技术的技术进步
    • 抑制因素
      • 与设备和治疗性血浆置换程序相关的成本
    • 机会
      • 神经肌肉疾病治疗血浆置换技术和免疫调节作用的进展
      • 儿科加护治疗中治疗性血浆置换 (TPE) 的需求快速成长
    • 任务
      • 与 TPE 成分分析程序相关的併发症
  • 市场区隔分析
    • 技术：膜分离是首选，但治疗性血浆置换
    • 适应症：广泛使用治疗性血浆置换治疗危及生命的血液疾病
    • 产品：耗材的技术进步必须与血浆置换设备和系统相容。
    • 最终用户：采血中心和血液成分供应商正在获得更大的用户群和大规模手术治疗的支持。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境
  • 客户客製化

第六章 治疗性血浆交换市场：依技术分类

  • 离心
  • 膜分离

第七章 治疗性血浆交易市场（依适应症分类）

  • 血液疾病
    • 非典型溶血性尿毒症综合症
    • 高黏滞症候群
    • 严重/有症状的冷球蛋白血症
    • 血栓性血小板低下紫斑症
  • 代谢紊乱
  • 神经系统疾病
    • 慢性脱髓鞘多发性神经炎
    • 格林-巴利综合症
    • 多发性硬化症
    • 重症肌无力
    • PANDAS
  • 肾臟疾病
    • 抗体介导的肾臟移植排斥反应
    • 古德帕斯特症候群
    • 韦格纳肉芽肿

第八章 治疗性血浆交换市场：副产品

  • 消耗品
  • 装置

第九章 治疗性血浆交换市场：依最终用户分类

  • 采血中心及血液成分供应商
  • 医院及输血中心

第十章 美洲治疗性血浆交易市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章 亚太地区治疗性血浆交易市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲的治疗性血浆交易市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Savage 医师将于 2024 年推出血浆置换减重法
    • HealthyLongevity.clinic 最近与 Dobri Kiprov 博士合作
    • MaxWell Clinic 提供治疗性血浆置换 (TPE) 作为失智症、阿兹海默症、记忆力衰退和自体免疫疾病的治疗选择。

公司名单

  • Asahi Kasei Medical Co., Ltd.
  • Haemonetics Corporation
  • CSL Behring
  • Kedrion Biopharma Inc.
  • Medica SPA
  • Elastrin Therapeutics, Inc.
  • B. Braun Melsungen AG
  • Pall Corporation
  • Medicap Clinic GmbH
  • Infomed SA
  • Terumo BCT, Inc.
  • Qingdao Haier Biomedical Co., Ltd
  • Mallinckrodt PLC
  • Fresenius Medical Care AG & Co. KGaA
  • Kaneka Corporation
  • MEISE Medizintechnik GmbH
  • Nikkiso Co., Ltd.
  • Grifols, SA
  • Sb-Kawasumi Laboratories, Inc.
  • Charles River Laboratories International, Inc.
  • Cerus Corporation
  • Plasma Technologies, LLC
  • Miltenyi Biotec
  • Bio Products Laboratory Ltd.
  • Baxter International Inc.
Product Code: MRR-BC0B37A58A34

The Therapeutic Plasma Exchange Market was valued at USD 792.04 million in 2023, expected to reach USD 878.53 million in 2024, and is projected to grow at a CAGR of 9.81%, to USD 1,525.84 million by 2030.

Therapeutic Plasma Exchange (TPE) is a vital medical procedure involving the removal, treatment, and reinfusion of plasma to manage various health conditions such as autoimmune diseases, neurological disorders, and hematological disorders. Its necessity arises from the procedure's ability to remove pathogenic substances from the blood, which is crucial for patients unresponsive to conventional treatments. TPE finds applications in treating diseases like Guillain-Barre Syndrome, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura, and Atypical Hemolytic Uremic Syndrome, with hospitals and specialty clinics being primary end-users. The market for TPE is growing, driven by increasing incidences of autoimmune diseases, advancements in healthcare infrastructure, and a rising aging population. Technological advancements like the development of more efficient and safer apheresis devices and increasing awareness of TPE's therapeutic benefits are key growth drivers. However, the market faces challenges such as high procedural costs, limited reimbursement policies, and the need for highly skilled healthcare professionals. Additionally, the scarcity of skilled technicians and limited accessibility in developing regions hinder growth. Despite these challenges, opportunities lie in expanding applications for emerging autoimmune conditions and innovating cost-effective and user-friendly apheresis devices. Investment in research and development, along with strategic collaborations and partnerships, could accelerate growth and widen the application scope. Companies can leverage data analytics to optimize procedures and enhance patient outcomes. Furthermore, telemedicine can support remote monitoring and post-treatment care, adding value to service delivery. However, regulations concerning medical device approval and the ethical implications of plasma procurement highlight areas requiring careful navigation. To stay competitive, companies should focus on personalized medicine approaches, integrating advanced technology to offer tailored therapeutic plasma exchange solutions that align with patient-specific needs.

KEY MARKET STATISTICS
Base Year [2023] USD 792.04 million
Estimated Year [2024] USD 878.53 million
Forecast Year [2030] USD 1,525.84 million
CAGR (%) 9.81%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Therapeutic Plasma Exchange Market

The Therapeutic Plasma Exchange Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Need of Therapeutic Plasma Exchange due to Rise in Prevalence of Autoimmune and Cardiac Diseases
    • Technical Advancement in Apheresis Technologies
  • Market Restraints
    • Cost Associated with the Devices and Therapeutic Plasma Exchange Procedures
  • Market Opportunities
    • Advancement in Therapeutic Plasma Exchange Technology and its Immunomodulatory Effect in Neuromuscular Diseases
    • Surge in Demand for Therapeutic Plasma Exchange (TPE) in Pediatric Intensive Care
  • Market Challenges
    • Complications Associated with the Apheresis Procedure in TPE

Porter's Five Forces: A Strategic Tool for Navigating the Therapeutic Plasma Exchange Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Therapeutic Plasma Exchange Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Therapeutic Plasma Exchange Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Therapeutic Plasma Exchange Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Therapeutic Plasma Exchange Market

A detailed market share analysis in the Therapeutic Plasma Exchange Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Therapeutic Plasma Exchange Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Therapeutic Plasma Exchange Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Therapeutic Plasma Exchange Market, highlighting leading vendors and their innovative profiles. These include Asahi Kasei Medical Co., Ltd., Haemonetics Corporation, CSL Behring, Kedrion Biopharma Inc., Medica S.P.A., Elastrin Therapeutics, Inc., B. Braun Melsungen AG, Pall Corporation, Medicap Clinic GmbH, Infomed SA, Terumo BCT, Inc., Qingdao Haier Biomedical Co., Ltd, Mallinckrodt PLC, Fresenius Medical Care AG & Co. KGaA, Kaneka Corporation, MEISE Medizintechnik GmbH, Nikkiso Co., Ltd., Grifols, S.A., Sb-Kawasumi Laboratories, Inc., Charles River Laboratories International, Inc., Cerus Corporation, Plasma Technologies, LLC, Miltenyi Biotec, Bio Products Laboratory Ltd., and Baxter International Inc..

Market Segmentation & Coverage

This research report categorizes the Therapeutic Plasma Exchange Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Centrifugation and Membrane Separation.
  • Based on Indication, market is studied across Hematologic Disorders, Metabolic Disorders, Neurological Disorders, and Renal Disorders. The Hematologic Disorders is further studied across Atypical Hemolytic Uremic Syndrome, Hyperviscosity Syndrome, Severe/Symptomatic Cryoglobulinemia, and Thrombotic Thrombocytopenic Purpura. The Neurological Disorders is further studied across Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, and PANDAS. The Renal Disorders is further studied across Antibody-mediated Renal Transplant Rejection, Goodpasture Syndrome, and Wegener's Granulomatosis.
  • Based on Product, market is studied across Consumables and Devices.
  • Based on End-user, market is studied across Blood Collection Centers & Blood Component Providers and Hospitals & Transfusion Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Need of Therapeutic Plasma Exchange due to Rise in Prevalence of Autoimmune and Cardiac Diseases
      • 5.1.1.2. Technical Advancement in Apheresis Technologies
    • 5.1.2. Restraints
      • 5.1.2.1. Cost Associated with the Devices and Therapeutic Plasma Exchange Procedures
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancement in Therapeutic Plasma Exchange Technology and its Immunomodulatory Effect in Neuromuscular Diseases
      • 5.1.3.2. Surge in Demand for Therapeutic Plasma Exchange (TPE) in Pediatric Intensive Care
    • 5.1.4. Challenges
      • 5.1.4.1. Complications Associated with the Apheresis Procedure in TPE
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Membrane separation are preferred selection while therapeutic plasma exchange
    • 5.2.2. Indication: Extensive usage of therapeutic plasma exchange for life threatening hematologic disorders
    • 5.2.3. Product: Technological advancement in consumables needs should to be compatible with their plasma exchange devices and systems
    • 5.2.4. End-user: Blood collection centers & blood component providers are commanding larger user base and support for large scale operative treatments
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Therapeutic Plasma Exchange Market, by Technology

  • 6.1. Introduction
  • 6.2. Centrifugation
  • 6.3. Membrane Separation

7. Therapeutic Plasma Exchange Market, by Indication

  • 7.1. Introduction
  • 7.2. Hematologic Disorders
    • 7.2.1. Atypical Hemolytic Uremic Syndrome
    • 7.2.2. Hyperviscosity Syndrome
    • 7.2.3. Severe/Symptomatic Cryoglobulinemia
    • 7.2.4. Thrombotic Thrombocytopenic Purpura
  • 7.3. Metabolic Disorders
  • 7.4. Neurological Disorders
    • 7.4.1. Chronic Inflammatory Demyelinating Polyneuropathy
    • 7.4.2. Guillain-Barre Syndrome
    • 7.4.3. Multiple Sclerosis
    • 7.4.4. Myasthenia Gravis
    • 7.4.5. PANDAS
  • 7.5. Renal Disorders
    • 7.5.1. Antibody-mediated Renal Transplant Rejection
    • 7.5.2. Goodpasture Syndrome
    • 7.5.3. Wegener's Granulomatosis

8. Therapeutic Plasma Exchange Market, by Product

  • 8.1. Introduction
  • 8.2. Consumables
  • 8.3. Devices

9. Therapeutic Plasma Exchange Market, by End-user

  • 9.1. Introduction
  • 9.2. Blood Collection Centers & Blood Component Providers
  • 9.3. Hospitals & Transfusion Centers

10. Americas Therapeutic Plasma Exchange Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Therapeutic Plasma Exchange Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Therapeutic Plasma Exchange Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Dr. Savage Introduces Plasma Exchange for 2024 Weight Loss
    • 13.3.2. HealthyLongevity.clinic recently partnered with Dr. Dobri Kiprov
    • 13.3.3. MaxWell Clinic offers Therapeutic Plasma Exchange (TPE) as a Treatment Option for Dementia, Alzheimer's, Memory Los, and Autoimmune Disease

Companies Mentioned

  • 1. Asahi Kasei Medical Co., Ltd.
  • 2. Haemonetics Corporation
  • 3. CSL Behring
  • 4. Kedrion Biopharma Inc.
  • 5. Medica S.P.A.
  • 6. Elastrin Therapeutics, Inc.
  • 7. B. Braun Melsungen AG
  • 8. Pall Corporation
  • 9. Medicap Clinic GmbH
  • 10. Infomed SA
  • 11. Terumo BCT, Inc.
  • 12. Qingdao Haier Biomedical Co., Ltd
  • 13. Mallinckrodt PLC
  • 14. Fresenius Medical Care AG & Co. KGaA
  • 15. Kaneka Corporation
  • 16. MEISE Medizintechnik GmbH
  • 17. Nikkiso Co., Ltd.
  • 18. Grifols, S.A.
  • 19. Sb-Kawasumi Laboratories, Inc.
  • 20. Charles River Laboratories International, Inc.
  • 21. Cerus Corporation
  • 22. Plasma Technologies, LLC
  • 23. Miltenyi Biotec
  • 24. Bio Products Laboratory Ltd.
  • 25. Baxter International Inc.

LIST OF FIGURES

  • FIGURE 1. THERAPEUTIC PLASMA EXCHANGE MARKET RESEARCH PROCESS
  • FIGURE 2. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. THERAPEUTIC PLASMA EXCHANGE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. THERAPEUTIC PLASMA EXCHANGE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. THERAPEUTIC PLASMA EXCHANGE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. THERAPEUTIC PLASMA EXCHANGE MARKET DYNAMICS
  • TABLE 7. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY CENTRIFUGATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY MEMBRANE SEPARATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HYPERVISCOSITY SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY SEVERE/SYMPTOMATIC CRYOGLOBULINEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY THROMBOTIC THROMBOCYTOPENIC PURPURA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY MYASTHENIA GRAVIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PANDAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY ANTIBODY-MEDIATED RENAL TRANSPLANT REJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY GOODPASTURE SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY WEGENER'S GRANULOMATOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HOSPITALS & TRANSFUSION CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 299. SWITZERLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 306. TURKEY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 313. UNITED ARAB EMIRATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)